Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Indication

Major Depressive Disorder

Clinical and regulatory intelligence for Major Depressive Disorder with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
6
Catalysts
1
Assets
5

Relevant assets

aripiprazole →
Baroque →
Medtronic →
Neurocrine →
Pramipexole →

Relevant companies

Cipla Ltd. →
NBI-1065845 →

Recent signals(6)

ClinicalAugust 7, 2026

Study on Theta Burst Stimulation in Major Depressive Disorder Using Advanced Imaging Techniques

The study will assess the effects of accelerated intermittent Theta Burst Stimulation on neurobiological mechanisms in MDD using advanced imaging.

ClinicalAugust 1, 2026

Baroque Music Therapy Shows Potential to Reduce Anxiety in Major Depressive Disorder Patients

A study is investigating the effects of Baroque music on reducing anxiety in patients with major depressive disorder.

ClinicalJuly 27, 2026

Medtronic's Percept PC DBS Study for Treatment Resistant Depression Initiated

A new study is investigating the use of Medtronic's Percept PC deep brain stimulation device for treatment resistant depression, focusing on local field potentials.

ClinicalJuly 15, 2026

Phase II Trial of Pramipexole vs Escitalopram for MDD in HIV Patients

A phase II trial is underway comparing pramipexole ER and escitalopram for treating MDD in HIV patients.

ClinicalJuly 13, 2026

Trial on Treatment Options for Major Depressive Disorder with TRD Initiated

A multi-site trial is comparing aripiprazole augmentation, rTMS augmentation, and switching to venlafaxine XR or Duloxetine for TRD patients.

ClinicalJune 24, 2026

Neurocrine's NBI-1065845 Shows Promise as Adjunctive Treatment for Major Depressive Disorder

A study is underway to assess the efficacy and safety of NBI-1065845 as an adjunctive treatment for Major Depressive Disorder.

Upcoming catalysts(1)

PDUFA Date

Johnson & Johnson — Caplyta

MDD approval would significantly expand Caplyta commercial footprint.

August 5, 2026 · NDA/BLA

Therapeutic areas

Major Depressive Disorder →
Mental Health →
Neurology →
Psychiatry →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.